CD274 and neoplasm: In addition, 18 out of 98 patients, 15 out of 82 PD-L1-positive patients, 13 of previously treated patients, and 3 of 15 PD-L1-negative patients had SD, leading to a disease control rate of 30.6% in the total population and 32.9% in the PD-L1-positive tumor population.